恩格列净和西格列汀治疗肥胖的2型糖尿病患者的临床效果比较  

Comparison of Clinical Effects of Empagliflozin and Sitagliptin in the Treatment of Obese Type 2 Diabetic Patients

作　　者：刘红丹[1] 陈海静[1] LIU Hong-dan;CHEN Hai-jing(Department of Endocrinology,the First Hospital of Fangshan District,Beijing,102400 China)

机构地区：[1]北京市房山区第一医院内分泌科,北京102400

出　　处：《糖尿病新世界》2021年第4期111-113,共3页Diabetes New World Magazine

摘　　要：目的比较恩格列净联合二甲双胍和西格列汀联合二甲双胍治疗合并肥胖的2型糖尿病患者的疗效和安全性。方法选取2019年3月—2020年3月该院诊治的合并肥胖的2型糖尿病患者48例,按随机数字表将患者分为两组,A组24例,予恩格列净联合二甲双胍治疗,B组24例,予西格列汀联合二甲双胍治疗,疗程12周;对比两组患者治疗后的临床效果。结果治疗后两组患者的FPG、2 hPG、HbA1c水平均显著低于治疗前,差异有统计学意义(P<0.05),但两组间差异无统计学意义(P>0.05)。治疗后A组的三酰甘油、体质指数低于B组,差异有统计学意义(P<0.05);治疗后A组的高密度脂蛋白胆固醇水平高于B组,差异有统计学意义(P<0.05);治疗后A组总胆固醇、低密度脂蛋白胆固醇水平与治疗前及B组比较差异无统计学意义(P>0.05)。两组患者均未发生明显不良反应。结论二甲双胍单药治疗效果不佳的、合并肥胖的2型糖尿病患者用恩格列净和西格列汀治疗降糖效果相当,均不易发生低血糖,但恩格列净还可降低患者体重,改善血脂。Objective To compare the efficacy and safety of empagliflozin combined with metformin and sitagliptin combined with metformin in the treatment of obese type 2 diabetic patients.Methods A total of 48 obese type 2 diabetic patients diagnosed and treated in this hospital from March 2019 to March 2020 were divided into two groups according to the random number table,group A with 24 cases,and treated with empagliflozin combined with metformin.24 patients in group B were treated with sitagliptin combined with metformin for 12 weeks;the clinical effects of the two groups were compared.Results After treatment,the FPG,2 hPG,and HbA1c levels of the two groups of patients were significantly lower than before treatment,the difference was statistically significant(P<0.05),but the difference between the two groups was not statistically significant(P>0.05).After treatment,the triacylglycerol and body mass index of group A were lower than group B,and the difference was statistically significant(P<0.05);after treatment,the high-density lipoprotein cholesterol level of group A was higher than that of group B,and the difference was statistically significant(P<0.05);after treatment,the total cholesterol and low-density lipoprotein cholesterol levels of group A were not significantly different from those before treatment and group B(P>0.05).No obvious adverse reactions occurred in the two groups of patients.Conclusion Enpagliflozin and sitagliptin have the same antidiabetic effect in treating obese type 2 diabetic patients with poor metformin monotherapy,and both of them are less likely to have hypoglycemia.However,empagliflozin can also reduce the weight of patients and improve blood lipids.

关 键 词：恩格列净 西格列汀 肥胖 2型糖尿病 

分 类 号：R587.2[医药卫生—内分泌]